Last reviewed · How we verify
Westcort (HYDROCORTISONE VALERATE)
Hydrocortisone Valerate (Westcort), marketed by Sun Pharma, is a corticosteroid indicated for corticosteroid-responsive dermatoses, competing in a segment with several off-patent generics such as alclometasone dipropionate and amcinonide. Its key strength lies in its mechanism of action through the glucocorticoid receptor, which effectively triggers anti-inflammatory responses, potentially offering a differentiated efficacy profile. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased generic competition and revenue erosion.
At a glance
| Generic name | HYDROCORTISONE VALERATE |
|---|---|
| Sponsor | Sun Pharma |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
- Corticosteroid-responsive dermatoses
Common side effects
- Worsening of condition
- Transient itching
- Irritation
- Redness
- Eczema
- Pruritis
- Stinging
- Dry skin
- Burning
- Dryness
- Folliculitis
- Acneiform eruptions
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (PHASE1)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Westcort CI brief — competitive landscape report
- Westcort updates RSS · CI watch RSS
- Sun Pharma portfolio CI